title: Regional cerebral blood flow and cerebrovascular reactivity in IDDM.
abstract: OBJECTIVE
  To investigate both rCBF and cerebrovascular reactivity, evaluated as pre- and post-ACZ rCBF differences in a group of IDDM patients with differences in duration of disease and severity of complications.
  
  
  METHODS
  rCBF was measured by the 133Xenon inhalation method in 20 IDDM patients and in 15 healthy control subjects before and after an intravenous injection of ACZ, a carbonic anhydrase inhibitor commonly used to assess cerebrovascular reactivity.
  
  
  RESULTS
  Basal global CBF (the mean of 32 regional values) was within the normal range in all patients but 1, who showed slight hyperperfusion; moreover, in 3 patients with long-lasting disease, some hypoperfused regions were found. ANOVA showed an inverse correlation between basal global CBF (P < 0.01) and duration of diabetes, but no correlation with Hb, MABP, serum glucose concentration, or GHb. Compared with control subjects, the percentage of global CBF increment after ACZ administration was significantly impaired in 4 patients and gave a borderline response in 2 patients; 4 of these poor ACZ responders had retinopathy, and 1 had suffered from a TIA. Duration of diabetes, Hb, MABP, serum glucose concentration, and GHb did not correlate with the percentage of post-ACZ global CBF changes, and did not differ among the 6 poor ACZ responders and the other diabetic patients or control subjects.
  
  
  CONCLUSIONS
  These results confirm that global CBF is within the normal range in most IDDM patients, although it is significantly influenced by the duration of diabetes; pathophysiological correlates of the altered cerebrovascular reactivity need to be further investigated. rCBF measurements, before and after ACZ administration, seem to represent a safe and reliable tool for assessing cerebrovascular function in IDDM.
authors.affiliation: Department of Motor Science-Neurophysiopathology, University of Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Rodriguez
authors.forename: F
authors.initials: F
authors.lastname: Nobili
authors.forename: M A
authors.initials: MA
authors.lastname: Celestino
authors.forename: S
authors.initials: S
authors.lastname: Francione
authors.forename: G
authors.initials: G
authors.lastname: Gulli
authors.forename: K
authors.initials: K
authors.lastname: Hassan
authors.forename: S
authors.initials: S
authors.lastname: Marenco
authors.forename: G
authors.initials: G
authors.lastname: Rosadini
authors.forename: R
authors.initials: R
authors.lastname: Cordera
mesh_terms: D000086:Acetazolamide; D000328:Adult; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D001921:Brain / Q000098:blood supply* / Q000000981:diagnostic imaging; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D011877:Radionuclide Imaging; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects; D014980:Xenon Radioisotopes
chemical_list: D001786:Blood Glucose; D014980:Xenon Radioisotopes; D000086:Acetazolamide